Stay Away from United Therapeutics
The biotech stock may be cheap, but it's no time to buy in.
The market destroyed United Therapeutics (UTHR) on Monday, sending the stock down about 63% in intraday trading. The sell-off was driven by Friday's innocuously titled press release: "United Therapeutics Plans Expected Transition to Commercial Operations." In the announcement, however, the company indicated that sales of its flagship Uniprost, which is expected to be approved by the Food and Drug Administration early in 2001, would probably total $10-$20 million in the product's first year on the market--much lower than earlier estimates. The release also said United's chief operating officer, James Crow, and its executive vice president for business development, Gilles Cloutier, would both be leaving early next year.
What it Means for Investors
Although we love bargains in the biotech sector, we believe that United Therapeutics has too many lingering questions to make it a compelling pick right now.
The double whammy of downward revenue projections and the loss of two executives makes United Therapeutics unappealing. The company is facing some serious potential competitors in the pulmonary hypertension market, such as Swiss biotech firm Actelion. On the bright side, United does have two other products, Beraprost and Ketotop, in late-stage human trials, but at this point it's not clear that these products can offset the lost revenue from a potentially slow-growing Uniprost. Thus, we believe investors are better off looking elsewhere at present.
Emily Hall does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.